Core Viewpoint - The diagnostic reagent industry in China is experiencing fluctuations in market size due to the impact of COVID-19, with a projected recovery and growth expected by 2025, reaching a market size of 140 billion yuan, an 8% increase year-on-year [6][7]. Industry Overview - Diagnostic reagents are essential tools in medicine and biology for detecting diseases, infections, and other medical conditions through interactions with biological samples [4][6]. - The market is primarily dominated by in vitro diagnostic reagents, while in vivo diagnostics remain relatively small [6]. Market Size and Trends - The market for in vitro diagnostic reagents in China has shown an upward trend since 2015, with rapid growth from 2020 to 2022 due to the pandemic, but a 14% decline in 2023 due to reduced demand for COVID-19 diagnostic reagents [6][7]. - The market is expected to recover in 2024, with projections indicating a market size of 140 billion yuan by 2025, reflecting an 8% year-on-year growth [6][7]. Competitive Landscape - The diagnostic reagent market includes both domestic companies like Mindray Medical, Antu Bio, and Wanfu Bio, and international firms such as Roche Diagnostics and Abbott, all competing for market share [8]. - Domestic companies are noted for their strong R&D capabilities and significant market presence [8]. Industry Development Stages - The diagnostic reagent industry in China has progressed through four stages: nascent, initial, extensive development, and rapid growth, with significant advancements in technology and regulatory improvements since the 21st century [5]. Industry Chain - The industry chain consists of upstream raw materials (diagnostic enzymes, antigens, antibodies, etc.), the midstream diagnostic reagent production, and downstream applications in medical institutions and third-party diagnostic organizations [6]. Market Segmentation - The in vitro diagnostic reagent market is segmented, with immunodiagnostic reagents holding a 32% market share, followed by molecular diagnostic reagents at 19%, and biochemical diagnostic reagents at 18% [7]. Future Trends - The industry is expected to focus on high-end product upgrades, with companies increasing R&D investments to enhance product value amidst price pressures from centralized procurement [9]. - There is a trend towards market penetration in lower-tier cities and global expansion, with domestic products entering emerging markets in Southeast Asia and Africa [10]. - The industry is evolving towards a model centered on clinical value and personalized medicine, integrating diagnostic solutions with treatment recommendations [11].

（文章来源：证券日报） 证券日报网讯 2月24日，利德曼在互动平台回答投资者提问时表示，截至2026年2月13日收盘，公司股 东人数为29496户。 ...

Group 1 - The core point of the article is that Lideman (300289) reported a total of 29,983 shareholders as of February 10, 2026 [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")于 2025 年 3 月 4 日召开第六届董事会第二次会议审议通过《关于使用闲置自有资金进行 委托理财的议案》，同意公司及子公司使用额度不超过人民币 70,000 万 元的暂时闲置自有资金进行委托理财，用于购买银行、证券公司、信托 公司、基金管理公司等金融机构发行的安全性高、流动性好、中低风险 的现金管理类产品或理财产品等，上述额度自公司董事会审议通过之日 起 12 个 月 内 可 循 环 滚 动 使 用 。 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的《关于使用闲置自有资金进行委托理财 的公告》（公告编号：2025-007）、《关于使用闲置自有资金进行委托理 财的进展公告》（公告编号：2025-027、2025-028、2025-031、2025-042、 2026-007）。 公司与上述银行不存在关联关系。 证券代码：300289 证券简称：利德曼 公告编号：2026-009 北京利德曼生化股份有限公司 关于使用闲置 ...

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [7]. Core Views - The recent policy from the National Healthcare Security Administration aims to transform the role of healthcare insurance from a payer to an innovator, significantly impacting the IVD industry by promoting solutions that integrate "testing + AI + services" [5][51]. - The domestic IVD industry is currently in a bottoming phase, with a strong focus on the growth potential of immunodiagnostics, particularly in chemiluminescence and molecular diagnostics such as PCR [5][51]. - The report highlights that the biochemical diagnostics sector in China has largely completed its localization process, reducing reliance on foreign technologies [5]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 0.14%, ranking 15th among 31 primary industries, while the IVD sector fell by 1.28% [2][10]. - The IVD sector's current PE (ttm) is 39.37X, with a PB (lf) of 1.80X, showing a slight decrease from the previous week [4][31]. Company Performance - Notable performers in the medical services sector include SAIKOSHI (+14.5%), Ruiang Gene (+3.1%), and Rendu Bio (+2.6%), while underperformers include Cap Bio (-6.8%) and Hotgen Bio (-6.4%) [3][26]. - The report suggests focusing on companies like YHLO Biotech and Shengxiang Bio in the immunodiagnostics and molecular diagnostics fields due to their growth potential [5][51]. Market Trends - The report indicates that the IVD industry is experiencing a shift towards integrating new technologies and payment methods, driven by recent policy changes [5][51]. - The overall IVD market is expected to continue its steady growth, with significant opportunities arising from the integration of AI and innovative products [5][51].

Core Viewpoint - Lideman announced the convening of its sixth board meeting on October 28, 2025, and the first extraordinary shareholders' meeting on November 21, 2025, to review the proposal for the re-election of Mr. Liao Zihua as a non-independent director and amendments to relevant documents [1] Group 1 - The company has completed the registration of its updated capital, which is now RMB 544.011487 million [1] - The company has filed for changes to its articles of association and board members in accordance with the latest registration requirements from the Beijing Economic and Technological Development Zone Market Supervision Administration [1] - The company has received a new business license issued by the Beijing Economic and Technological Development Zone Market Supervision Administration [1]

北京利德曼生化股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第六届董事会第六次会议、2025 年 11 月 21 日召开 2025 年第一次临时股东大会，审议通过《关于补选廖子华先生为公 司第六届董事会非独立董事的议案》《关于修订<公司章程>及附件的 议案》，内容详见刊登于巨潮资讯网（http://www.cninfo.com.cn）的相 关公告。根据公司相关股东大会决议内容，公司向北京经济技术开发 区市场监督管理局申请变更登记及备案。 近日，公司按照北京经济技术开发区市场监督管理局的最新变更 登记要求及核准情况，对《公司章程》和变更董事等事项进行备案； 完成最新注册资本的工商变更登记，公司注册资本变更为人民币 54,401.1487 万元，并取得北京经济技术开发区市场监督管理局换发 的《营业执照》。除上述事项外，公司原营业执照其它登记项目不变。 特此公告。 北京利德曼生化股份有限公司 证券代码：300289 证券简称：利德曼 公告编号：2026-008 北京利德曼生化股份有限公司 关于完成工商变更登记备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记 ...

Group 1 - The company, Lideman, reported that as of January 30, 2026, the number of shareholders reached 31,076 [2]

关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")于 2025 年 3 月 4 日召开第六届董事会第二次会议审议通过了《关于使用闲置自有资金进 行委托理财的议案》，同意公司及子公司使用额度不超过人民币 70,000 万元的暂时闲置自有资金进行委托理财，用于购买银行、证券公司、信 托公司、基金管理公司等金融机构发行的安全性高、流动性好、中低风 险的现金管理类产品或理财产品等，上述额度自公司董事会审议通过之 日起 12 个月内可循环滚动使用。内容详见公司在巨潮资讯网 （www.cninfo.com.cn）披露的《关于使用闲置自有资金进行委托理财 的公告》（公告编号：2025-007）、《关于使用闲置自有资金进行委托理 财的进展公告》（公告编号：2025-027、2025-028、2025-031、2025-042）。 一、公司使用闲置自有资金进行委托理财进展情况 公司于 2026 年 2 月 2 日将银行理财产品到期赎回，详情如下： | | 产品 | 类型 | 金额 （万 | ...

Core Viewpoint - The precision medicine sector experienced a decline of 1.88% on February 2, with Lide Man leading the drop [1] Market Performance - The Shanghai Composite Index closed at 4015.75, down 2.48% [1] - The Shenzhen Component Index closed at 13824.35, down 2.69% [1] Capital Flow - The precision medicine sector saw a net outflow of 615 million yuan from main funds, while retail investors contributed a net inflow of 525 million yuan [1] - Speculative funds recorded a net inflow of approximately 89.6 million yuan [1]